Content uploaded by Terence C Chua
Author content
All content in this area was uploaded by Terence C Chua on Dec 30, 2019
Content may be subject to copyright.
P0115 SYNCHRNOUS PERITONECTYOMY AND LIVER RESCTION
IN COLORECTAL CANCER
Nayef Alzahrani1, Terence Chua2, Rachel Kirby1, Jing Zhao3, Winston Liauw4,
David Morris2
1
St George Hospital, University of New South Wales, Sydney, Australia,
2
St
George Hospital, University of New South Wales, Sydney, Australia,
3
St George
Hospital, Kogarah, Australia,
4
St George Hospital, Sydney, Australia
Background: Cytoreductive surgery (CRS) and hepatectomy are accepted surgical
strategies to manage metastatic disease in colorectal cancer(CRC).The safety and
outcomes of patients undergoing both operative treatment to manage abdominal
oligometastatic disease from CRC is less well established.
Methods: Patients who underwent CRS and hepatectomy for CRC between 2005 and
2012 were retrieved from a prospectivedatabase for retrospective analysis.
Standardized surgical and pathological variable were examined to fulfill the study’s
endpoints of safety and efficacy of thistherapeutic strategy.
Results: Of 171 patients undergoing CRS for CRC.36 patients (21%) were managed
with a curative intent undergoing hepatectomy additionally. The median Peritoneal
carcinamatosis index (PCI) was 6 (range, 1-24). The Median number of liver metastasis
was 2 (range, 1-10), 31 patients (86%) underwent minor hepatic resection (less than or
equal to 3 lesions) and 5 patients (13.8%) underwent major hepatic resection.
4 patients (11%) received ablation using cryotherapy in addition to hepatectomy. The
overall median survival was 27.8 months (range, 1-47) with 1-, 2-, 3-year survival of
83%, 55%, 29% respectively. The median survival of patient with < =3 liver metastasis
was 28.7 (range, 17.9-34.9) and >3 liver metastasis was 22.1 (range, 20.3-35.3)
(P = 0.548). The mortality rate was 2.7% and major complication rate was 38.9%.
Conclusion: Additional hepatic surgery to eradicate liver metastasis in patients with
limited peritoneal metastasis from CRC may afford an encouraging survival outcome
in this group of patients with abdominal oligometastatic cancer.
© The Author 2013. Published by Oxford University Press on behalf of the European Society for Medical Oncology.
All rights reserved. For permissions, please email: journals.permissions@oup.com.
posters
posters Annals of Oncology 24 (4): iv38–iv121, 2013
doi:10.1093/annonc/mdt203.113
Downloaded from https://academic.oup.com/annonc/article-abstract/24/suppl_4/iv68/152294 by guest on 30 December 2019